Ropes & Gray: Nona Biosciences Announces Global License, Option Agreement With AstraZeneca
May 24, 2024
May 24, 2024
BOSTON, Massachusetts, May 24 -- Ropes and Gray, a law firm, issued the following news:
Ropes & Gray advised Nona Biosciences in a license agreement with AstraZeneca for preclinical monoclonal antibodies that will be used to develop targeted oncology therapies using Nona's antibody discovery platform. The transaction was announced on May 22.
Under the agreement, Nona will receive $19 million upon completion of the transaction. Nona is eligible to receive an addition . . .
Ropes & Gray advised Nona Biosciences in a license agreement with AstraZeneca for preclinical monoclonal antibodies that will be used to develop targeted oncology therapies using Nona's antibody discovery platform. The transaction was announced on May 22.
Under the agreement, Nona will receive $19 million upon completion of the transaction. Nona is eligible to receive an addition . . .